Pangea Biomed
Tel Aviv
About Pangea Biomed
Pangea Biomed combines ML and RNA sequencing to offer personalized cancer treatment. The company's ENLIGHT platform can surface relevant biological insights to pinpoint the best path forward in combating a patient's cancer by combining the hidden power of RNA sequencing with ML-enabled network effects. It examines the molecular context in which targeted therapies operate, looking beyond actionable genomic abnormalities. Pangea's goal is to democratize precision oncology, bringing deep tumor intelligence to drug development and to treatment nomination for patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.0M
- Funding stage: Seed
- Last round: Seed (Dec 2022)
- Website: pangeabiomed.com
- Phone: 03-5441755
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/pangea-biomed-62276 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.